News & Perspective

Aug 15, 2018

Aug 15, 2018

News Scan for Aug 15, 2018

USDA avian flu compensation plan
Boosting ID physician-scientists

Apr 23, 2010

Apr 23, 2010

H1N1 LESSONS LEARNED Pandemic underscored influenza's unpredictability

Editor's Note: This is the first of a series of articles reviewing the world's experience with pandemic H1N1 influenza and what we've learned in the past year. Look for further installments in the days to come.

(CIDRAP News) – A year's experience with the 2009 H1N1 influenza virus has underscored the endless unpredictability of flu.

Feb 03, 2009

Feb 03, 2009

Experts weigh new H5N1 vaccine strategies

(CIDRAP News) – At an Infectious Diseases Society of America (IDSA) symposium in Washington, DC, today on seasonal and pandemic influenza, a group of experts fielded questions from reporters on some of the new trends and emerging issues, including prepandemic strategies for H5N1 avian influenza vaccines, now that some countries are stockpiling them.

Oct 29, 2008

Oct 29, 2008

Experts stress vigilance over emerging, unpredictable diseases

See related article posted today: "US urged to launch major campaign against emerging diseases"

– WASHINGTON, DC (CIDRAP News) – Health authorities must remain alert to new and renascent disease threats, experts warned this week at an international medical meeting.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Nov 02, 2007

Nov 02, 2007

THE PANDEMIC VACCINE PUZZLE Part 7: Time for a vaccine 'Manhattan Project'?

Editor's note: This is the last in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time.

Oct 25, 2007

Oct 25, 2007

THE PANDEMIC VACCINE PUZZLE Bibliography

Editor's note: This is the bibliography to a seven-part series launched October 25, 2007, investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Feb 02, 2007

Feb 02, 2007

Experts give qualified praise to new pandemic guidance

(CIDRAP News) – New federal recommendations on nonpharmaceutical measures communities can use to fight an influenza pandemic are drawing generally high marks from public health officials and others, but they say the plan spells a massive workload for local planners.

Oct 04, 2006

Oct 04, 2006

Groups call for pandemic flu vaccine 'master plan'

(CIDRAP News) – Public health and infectious disease experts today called on the United States to develop a "master plan" for development of pandemic influenza vaccines in order to translate scientific advances more rapidly into improved pandemic preparedness.

Nov 01, 2005

Nov 01, 2005

Bush asks $7.1 billion to prepare for flu pandemic

Editor's Note: This is an expanded version of a story published earlier today ().

(CIDRAP News) – President George W. Bush today proposed $7.1 billion in spending to prepare for an influenza pandemic, including $5 billion for vaccines and drugs, as his administration released an outline of its preparedness strategy.

Pages

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»